AVTE vs. AVBP, IGMS, CDMO, APLT, ATXS, PHAT, ABUS, CMPS, CALT, and LRMR
Should you be buying Aerovate Therapeutics stock or one of its competitors? The main competitors of Aerovate Therapeutics include ArriVent BioPharma (AVBP), IGM Biosciences (IGMS), Avid Bioservices (CDMO), Applied Therapeutics (APLT), Astria Therapeutics (ATXS), Phathom Pharmaceuticals (PHAT), Arbutus Biopharma (ABUS), COMPASS Pathways (CMPS), Calliditas Therapeutics AB (publ) (CALT), and Larimar Therapeutics (LRMR). These companies are all part of the "pharmaceutical preparations" industry.
ArriVent BioPharma (NASDAQ:AVBP) and Aerovate Therapeutics (NASDAQ:AVTE) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, institutional ownership, community ranking, profitability, dividends, valuation, analyst recommendations, earnings and media sentiment.
Aerovate Therapeutics received 9 more outperform votes than ArriVent BioPharma when rated by MarketBeat users. However, 100.00% of users gave ArriVent BioPharma an outperform vote while only 64.00% of users gave Aerovate Therapeutics an outperform vote.
ArriVent BioPharma presently has a consensus price target of $29.25, suggesting a potential upside of 66.19%. Aerovate Therapeutics has a consensus price target of $49.33, suggesting a potential upside of 137.18%. Given ArriVent BioPharma's higher possible upside, analysts plainly believe Aerovate Therapeutics is more favorable than ArriVent BioPharma.
Aerovate Therapeutics' return on equity of 0.00% beat ArriVent BioPharma's return on equity.
In the previous week, ArriVent BioPharma had 4 more articles in the media than Aerovate Therapeutics. MarketBeat recorded 9 mentions for ArriVent BioPharma and 5 mentions for Aerovate Therapeutics. Aerovate Therapeutics' average media sentiment score of 0.59 beat ArriVent BioPharma's score of 0.14 indicating that ArriVent BioPharma is being referred to more favorably in the media.
9.5% of ArriVent BioPharma shares are owned by institutional investors. 19.3% of Aerovate Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Summary
ArriVent BioPharma beats Aerovate Therapeutics on 8 of the 11 factors compared between the two stocks.
Get Aerovate Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for AVTE and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AVTE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Aerovate Therapeutics Competitors List
Related Companies and Tools
